'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

Jason Mast

Editor

Steve Holtzman’s last retirement lasted about 4 months. He promises the new one will be a bit longer.

There are big plans for version 2.0: He is going to date his wife.

“That’s the quote: ‘What’s he going to do? He’s going to date his wife more!” Holtzman said in an interview with Endpoints News. “And I’m completely serious.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

Jason Mast

Editor

Unlock this article instantly by becoming a free subscriber.

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says

'What's he go­ing to do? He's go­ing to date his wife more!' Steve Holtz­man on Deci­bel and leav­ing biotech (again)

Jason Mast

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

GSK unveils long-term Shingrix data as shingles competition heats up

Senate bill targeting WuXi won't affect federal spending, CBO says